"FDA accelerated approval of Marqibo® (vinCRIStine sulfate LIPOSOME injection) is Talon's most important achievement to date," stated Steven R. Deitcher, M.D., President, Chief Executive Officer and Board Member of Talon. "The patient population Marqibo® will be serving is in need of new treatment options. We are in the process of evaluating a number of paths to commercialize Marqibo®, including a potential strategic transaction, licensing agreement, or a Talon launch."